Loading...
•
Dec 31, 2021
United Therapeutics Q4 2021 Earnings Report
Reported double-digit percentage revenue and patient count growth in full-year 2021.
Key Takeaways
United Therapeutics Corporation announced its Q4 and full year 2021 financial results. Full year total revenues rose to $1,686 million, driven by an all-time high in U.S. patients being treated with the company’s treprostinil-based therapies during the fourth quarter of 2021.
Full year total revenues rose to $1,686 million.
U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2021.
Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022.
Major amendment to Tyvaso DPI™ NDA pushes FDA decision date to May 2022.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
Revenue by Segment
Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.com Forward Guidance
United Therapeutics is focused on expanding its patient reach and advancing its research and development programs.
Positive Outlook
- Targeting 6,000 U.S. patients on Tyvaso by the end of 2022.
- Targeting 25,000 patients on all of our therapies by the end of 2025.
- Ongoing phase 3 PERFECT study evaluating Tyvaso in patients with WHO Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
- Enrolling two phase 3 clinical studies to support the potential approval of oral ralinepag for PAH.
- Working to create an unlimited supply of manufactured organs for transplantation.
Challenges Ahead
- Major amendment to Tyvaso DPI™ NDA pushes FDA decision date to May 2022.
- Risk that the company will not obtain the necessary FDA approvals to launch Tyvaso DPI.
- The recent transplants of our xenoheart and xenokidney products demonstrate the tremendous potential of our business model for the second half of the 2020s and beyond.
- FDA requested additional information concerning the pulmonary safety of Tyvaso DPI related to a pending Citizen's Petition.
- Subject to risks and uncertainties described in periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income